BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15531548)

  • 1. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
    Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
    Da Silva AM; Maciel RM; Da Silva MR; Toledo SR; De Carvalho MB; Cerutti JM
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5438-43. PubMed ID: 14602786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
    Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
    Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
    Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
    J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
    Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
    Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The newly detected mutations in the RET proto-oncogene in exon 16 as a cause of sporadic medullary thyroid carcinoma.
    Jindrichova S; Kodet R; Krskova L; Vlcek P; Bendlova B
    J Mol Med (Berl); 2003 Dec; 81(12):819-23. PubMed ID: 14618242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medullary thyroid carcinoma in a child with a new RET mutation and a RET polymorphism.
    Vandenbosch K; Renard M; Uyttebroeck A; Sciot R; Matthijs G; Legius E
    Genet Couns; 2005; 16(1):95-100. PubMed ID: 15844786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma.
    Huang CN; Wu SL; Chang TC; Huang SH; Chang TJ
    J Formos Med Assoc; 1998 Aug; 97(8):541-6. PubMed ID: 9747064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
    Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L
    Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas.
    Uchino S; Noguchi S; Adachi M; Sato M; Yamashita H; Watanabe S; Murakami T; Toda M; Murakami N; Yamashita H
    Jpn J Cancer Res; 1998 Apr; 89(4):411-8. PubMed ID: 9617347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma.
    Dourisboure RJ; Belli S; Domenichini E; Podestá EJ; Eng C; Solano AR
    Thyroid; 2005 Jul; 15(7):668-71. PubMed ID: 16053382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mutations of ret-proto-oncogene in thyroid medullary carcinoma].
    Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
    Dtsch Med Wochenschr; 1997 Feb; 122(6):143-9. PubMed ID: 9081799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.